TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33066811

Group type: EXPERIMENTAL
Intervention: Music-based synchronous finger tapping (SFT) intervention for 25 minutes daily for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (details not specified)
Number of subjects: 0
Study: 34895700

Group type: EXPERIMENTAL
Intervention: 40 mg of relugolix (REL) orally once a day for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3.75 or 1.88 mg of leuprorelin (LEU) subcutaneously every 4 weeks for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg of relugolix (REL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3.75 or 1.88 mg of leuprorelin (LEU)
Number of subjects: 0
Study: 33738561

Group type: EXPERIMENTAL
Intervention: Decompressive craniotomy (DCO)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Decompressive craniectomy (DC)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: DCO techniques
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Interest in randomized trial
Number of subjects: 208
Study: 34028361

Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 128
Study: 32931661

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 11345
Study: 35637595

Group type: EXPERIMENTAL
Intervention: Behavioural intervention (education/promotional messages)
Number of subjects: 8992

Group type: EXPERIMENTAL
Intervention: Environmental intervention (chilled water station)
Number of subjects: 8992

Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 8992

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 8992
Study: 34105207

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day; days 1–14; 21 days per cycle)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 32281941

Group type: EXPERIMENTAL
Intervention: Behavioral intervention supported by a mobile health app
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mobile health app
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 35570513

Group type: EXPERIMENTAL
Intervention: Tele-Mindfulness Based Cognitive Therapy (tele-MBCT), 8 weekly live online sessions, average daily practice of 23.58±45.71 minutes.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 26
Study: 33599270

Group type: EXPERIMENTAL
Intervention: Switch to a PI-based second-line regimen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continue on first-line therapy (control)
Number of subjects: 80
Study: 32947459

Group type: EXPERIMENTAL
Intervention: Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, Vaseline (applied to nonlesional skin of one forearm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No moisturizer (applied to the opposite forearm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moisturizers (general intervention)
Number of subjects: 20
Study: 36086755

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and electronic moxibustion (EM) cotreatment, 3 times a week for 6 weeks, alongside previously prescribed alpha blocker.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group continued to use the previously prescribed alpha blocker alone for 6 weeks.
Number of subjects: 28
Study: 32571960

Group type: EXPERIMENTAL
Intervention: PE+LUS (Physical Examination + Lung Ultrasound)
Number of subjects: 244

Group type: COMPARATOR
Intervention: PE only (Physical Examination only)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: PE+LUS
Number of subjects: 244

Group type: COMPARATOR
Intervention: PE only
Number of subjects: 244
Study: 36255063

Group type: EXPERIMENTAL
Intervention: Experimental group (answered anchoring tasks immediately after being awakened at nighttime)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (answered anchoring tasks at daytime)
Number of subjects: 104
Study: 32690388

Group type: EXPERIMENTAL
Intervention: Conservative strategy for non-true bifurcation lesions
Number of subjects: 206

Group type: COMPARATOR
Intervention: Aggressive strategy for non-true bifurcation lesions
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Conservative strategy for true bifurcation lesions
Number of subjects: 206

Group type: COMPARATOR
Intervention: Aggressive strategy for true bifurcation lesions
Number of subjects: 206
Study: 33824084

Group type: EXPERIMENTAL
Intervention: Prone Positioning (PP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 114
Study: 33579855

Group type: EXPERIMENTAL
Intervention: Attendance at a gym or sports club
Number of subjects: 455258

Group type: EXPERIMENTAL
Intervention: Attendance at religious group
Number of subjects: 455258
Study: 32584510

Group type: EXPERIMENTAL
Intervention: Planning intervention
Number of subjects: 225
Study: 32917251

Group type: EXPERIMENTAL
Intervention: Vessel-sparing anastomotic repair (vsAR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transecting anastomotic repair (tAR)
Number of subjects: 100
Study: 33544052

Group type: EXPERIMENTAL
Intervention: Tailored temporal message frames that align with individuals' CFC
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Operationalization of risk perception (susceptibility only, severity only, or combination of the two)
Number of subjects: 450
Study: 35446230

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for generalized anxiety disorder (GAD)
Number of subjects: 80
Study: 33577388

Group type: EXPERIMENTAL
Intervention: Conventional bleaching+antioxidant with PIPS-activated irrigation (CB-PIPSI)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Modified bleaching+antioxidant with PIPS-activated irrigation (MB-PIPSI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (no bleaching/antioxidant)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Conventional bleaching only (CB)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Modified bleaching only (MB)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Conventional bleaching+antioxidant with needle irrigation (CB-NI)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Modified bleaching+antioxidant with needle irrigation (MB-NI)
Number of subjects: 105
Study: 32998206

Group type: EXPERIMENTAL
Intervention: Magnesium creatine chelate (MgCr‐C) supplementation, 5500 mg (0.07 g/kg/d) in 4 capsules per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (corn starch in identical 4 capsules)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Magnesium creatine chelate (MgCr‐C) supplementation
Number of subjects: 20
Study: 35747502

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor-targeted therapy
Number of subjects: 858

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 858
Study: 32901962

Group type: EXPERIMENTAL
Intervention: Root canal treatment with tissue-level restoration (TL group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Root canal treatment with normal occlusal contacts (OC group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (healthy patients with root canal treatments)
Number of subjects: 65
Study: 34018096

Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 5%)
Number of subjects: 94

Group type: COMPARATOR
Intervention: < 5% weight loss
Number of subjects: 94
Study: 32013946

Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention for community health workers (CHWs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 35421771

Group type: EXPERIMENTAL
Intervention: Constant low-temperature cold spray (programme A; n = 47)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Low-to-normal temperature spray (programme B; n = 49)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual care (control group; n = 49)
Number of subjects: 145
Study: 34061938

Group type: EXPERIMENTAL
Intervention: 1 simulation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 2 simulations
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 3 simulations
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 69
Study: 35076746

Group type: EXPERIMENTAL
Intervention: Microdebrider‐assisted turbinoplasty (MAT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Quantum molecular resonance (QMR)
Number of subjects: 70
Study: 32890647

Group type: EXPERIMENTAL
Intervention: Fusion imaging with a mobile flat plane sensor (Cios Alpha, Siemens) and angionavigation station (EndoNaut, Therenva)
Number of subjects: 41
Study: 35463348

Group type: EXPERIMENTAL
Intervention: Reduced-dose chemoradiotherapy (rdCRT) (56 Gy) with weekly carboplatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (sdCRT) (70 Gy)
Number of subjects: 20
Study: 32381186

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2488

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2488

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES) in small vessels
Number of subjects: 2488

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) in small vessels
Number of subjects: 2488
Study: 35307727

Group type: EXPERIMENTAL
Intervention: Oral enteral nutrition combined with microbial preparations
Number of subjects: 160

Group type: COMPARATOR
Intervention: Traditional intestinal preparation (control)
Number of subjects: 160
Study: 35535772

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Insomnia (ACT‐I)
Number of subjects: 37
Study: 33951124

Group type: EXPERIMENTAL
Intervention: polyethylenglycol 4L (PEG)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: oral sulfate solution (OSS)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: 2L polyethylenglycol + ascorbate (2L‐PEG/Asc)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: magnesium citrate + sodium picosulfate (MCSP)
Number of subjects: 431
Study: 32184607

Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 1-Month (PP1M)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 3-Month (PP3M)
Number of subjects: 1016
Study: 36166682

Group type: EXPERIMENTAL
Intervention: (R)-propafenone
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: (S)-propafenone
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 34191016

Group type: EXPERIMENTAL
Intervention: Mel4‐coated antimicrobial contact lenses (MACLs)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Uncoated control contact lenses
Number of subjects: 176
Study: 32306008

Group type: EXPERIMENTAL
Intervention: Enteral nutrition support in addition to chemotherapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 118
Study: 36283797

Group type: EXPERIMENTAL
Intervention: Respiratory distress symptom intervention (RDSI)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 263
Study: 36355652

Group type: EXPERIMENTAL
Intervention: Training (workshops and ongoing consultations)
Number of subjects: 117

Group type: COMPARATOR
Intervention: No training
Number of subjects: 117
Study: 34635178

Group type: EXPERIMENTAL
Intervention: Enhanced ATTC strategy (including Pay-for-Performance and Implementation & Sustainment Facilitation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Addiction Technology Transfer Center (ATTC) Network implementation strategy (control condition)
Number of subjects: 30
Study: 35606883

Group type: EXPERIMENTAL
Intervention: Evolocumab (140mg) administration once within 72 h before CABG
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no administration)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Evolocumab (140mg) administration
Number of subjects: 100
Study: 33533487

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Ki-67 assessment
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Combination of MRI and Ki-67
Number of subjects: 401
Study: 32291649

Group type: EXPERIMENTAL
Intervention: Heterogeneous condition (different synesthetic colors for familiar graphemes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Homogeneous condition (same synesthetic color for familiar graphemes)
Number of subjects: 0
Study: 35339669

Group type: EXPERIMENTAL
Intervention: Double-blind peppermint oil
Number of subjects: 173

Group type: COMPARATOR
Intervention: Double-blind placebo
Number of subjects: 173

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 173
Study: 34479601

Group type: EXPERIMENTAL
Intervention: IFN‐?1a (11?g or 3MIU) injected subcutaneously at day 1, 3, 7, and 10 in addition to standard of care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IFN‐?1a
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study: 32141389

Group type: EXPERIMENTAL
Intervention: Intermittent second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as two times four cycles)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Continuous second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as eight consecutive cycles)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Intermittent second-line chemotherapy
Number of subjects: 420

Group type: COMPARATOR
Intervention: Continuous second-line chemotherapy
Number of subjects: 420
Study: 36460046

Group type: EXPERIMENTAL
Intervention: Velocity-based RT session with 10% velocity loss (VL10)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional 1-repetition maximum-based RT session to failure (TRF)
Number of subjects: 15
Study: 33478112

Group type: EXPERIMENTAL
Intervention: C+ (enzyme-containing toothpaste with glucose oxidase and D-glucose with Citrox)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SLS (sodium lauryl sulfate-containing toothpaste)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reference (toothpaste without SLS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: C− (enzyme-containing toothpaste with glucose oxidase and D-glucose without Citrox)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 20
Study: 33171964

Group type: EXPERIMENTAL
Intervention: Aspartame (0.425 g, 14% of ADI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sucralose (0.136 g, 20% of ADI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aspartame and Sucralose
Number of subjects: 17
Study: 35690655

Group type: EXPERIMENTAL
Intervention: Surgical face mask (SM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Filtering face piece (FFP2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No mask (NM)
Number of subjects: 23
Study: 34563875

Group type: EXPERIMENTAL
Intervention: Initial hydroxyurea treatment for children with SCA and abnormal transcranial Doppler (TCD) velocities
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Capacity-building component of the trials
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Ongoing TCD-based screening and funding for hydroxyurea
Number of subjects: 679
Study: 35887829

Group type: EXPERIMENTAL
Intervention: Optilyte® infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Geloplasma® infusion
Number of subjects: 25
Study: 32356211

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride with tricalcium phosphate (TCP)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride with xylitol‐coated calcium and phosphate (CXP)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 5% sodium fluoride (SF) control group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride with casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP)
Number of subjects: 92
Study: 35726497

Group type: EXPERIMENTAL
Intervention: Posttherapeutic CBT skills usage frequency
Number of subjects: 241

Group type: COMPARATOR
Intervention: Supported iCBT
Number of subjects: 241
Study: 32890855

Group type: EXPERIMENTAL
Intervention: Anodal tDCS on dorsal pathway
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Anodal tDCS on ventral pathway
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 34344355

Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention
Number of subjects: 9
Study: 35724843

Group type: EXPERIMENTAL
Intervention: Báa nnilah intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study: 32481239

Group type: EXPERIMENTAL
Intervention: Sensorimotor and gait training for eight weeks (3 days/week) along with diabetes and foot care education
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diabetes and foot care education only
Number of subjects: 38
Study: 36096912

Group type: EXPERIMENTAL
Intervention: Digital complete dentures (CDs) fabricated from intraoral scan data
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional complete dentures (CDs) fabricated by conventional workflow
Number of subjects: 8
Study: 33065163

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 143
Study: 35211840

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 44
Study: 36259475

Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg/day, oral)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ET (Cycle ergometer, moderate intensity, 40-60% VO2 peak, three sessions/week for six weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MitoQ+ET
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 35618267

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (NR)
Number of subjects: 11499
Study: 33440972

Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation without propofol infusion (group Sev)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol infusion (group Pro)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 32532321

Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (spectacles or contact lenses)
Number of subjects: 0
Study: 33663735

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 3660
Study: 35157226

Group type: EXPERIMENTAL
Intervention: NORTH STAR prevention system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Assessment-and-feedback-only condition
Number of subjects: 24
Study: 34776184

Group type: EXPERIMENTAL
Intervention: Manorah training (45 min/day, 3 days/week for 4 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 32144059

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Anesthesia (TEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-Injection Paravertebral Block (PVB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paravertebral Catheter
Number of subjects: 0
Study: 35725863

Group type: EXPERIMENTAL
Intervention: High-level tidal volume (HLVT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-level pressure support (HLPS)
Number of subjects: 26
Study: 35655257

Group type: EXPERIMENTAL
Intervention: MASK-ED™ simulation (used in 5 out of 32 tutorials, 16%)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Role-play with peers (control group)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MASK-ED™ simulation (experimental group)
Number of subjects: 144
Study: 32710391

Group type: EXPERIMENTAL
Intervention: CT-P13 (biosimilar infliximab) given as a single infusion of 5 to 10 mg/kg
Number of subjects: 21
Study: 35907935

Group type: EXPERIMENTAL
Intervention: Virtual reality therapy (VRT) - active content
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Virtual reality therapy (VRT) - passive content
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall VRT experience
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 35
Study: 33788933

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 4103

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 4103

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 4103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4103
Study: 32860031

Group type: EXPERIMENTAL
Intervention: Vupanorsen 40 mg Q4W
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Vupanorsen 80 mg Q4W
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Vupanorsen 20 mg QW
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 33837592

Group type: EXPERIMENTAL
Intervention: LL-BFR training (9 sessions of low-load blood flow restricted exercise)
Number of subjects: 18

Group type: COMPARATOR
Intervention: SHAM-BFR training (equal training with sham vascular occlusion)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both LL-BFR and SHAM-BFR training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (for muscle biopsy analysis)
Number of subjects: 18
Study: 32152347

Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) with anode over left-dorsolateral prefrontal cortex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Number of subjects: 60
Study: 34561058

Group type: EXPERIMENTAL
Intervention: Lifestyle education program for biologically male participants
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lifestyle education program for biologically female participants
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no lifestyle education)
Number of subjects: 75